Topics

Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Fractures, Bone, Date of authorisation: 23/08/2012, Revision: 9, Status: Authorised

11:58 EDT 2 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Fractures, Bone, Date of authorisation: 23/08/2012, Revision: 9, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Fractures, Bone, Date of authorisation: 23/08/2012, Revision: 9, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Zoledronic acid Mylan, zoledronic acid, Fractures, Bone, Date of authorisation: 23/08/2012, Revision: 9, Status: Authorised"

Quick Search

Relevant Topic

Osteoporosis
Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...